Log In
BCIQ
Print this Print this
 

DTP3 (KES-0001)

  Manage Alerts
Collapse Summary General Information
Company Kesios Therapeutics Ltd.
DescriptionD-tripeptide that inhibits formation of the GADD45B/MKK7 complex
Molecular Target Mitogen-activated protein kinase kinase 7 (MAP2K7) (MKK7) ; Growth arrest and DNA-damage-inducible 45 beta (GADD45B)
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPreclinical
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today